EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Another piece of the evidence puzzle: is prostate-specific membrane antigen PET–CT a valuable tool for risk stratification?

Armin Atzinger, Florian Rosar

The Lancet Medical Imaging & Theranostics · 2026

DOI: 10.1016/j.lanmit.2026.100008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Lancet Medical Imaging & Theranostics, 2026. Verfasst von Armin Atzinger und 1 weiteren Autor:innen. Die Arbeit nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A post-hoc analysis of the randomised phase 3 RAPID trial, published in The Lancet Medical Imaging & Theranostics by Holger Einspieler and colleagues, provides important prospective evidence regarding the use of prostate-specific membrane antigen (PSMA) PET–CT in detecting clinically significant primary prostate cancer.1 As molecular imaging is increasingly expanding beyond conventional tumour staging toward refined disease characterisation and individualised treatment stratification, these findings represent a step toward personalised, evidence-based medicine.

Zitieren

APA

Atzinger, A., & Rosar, F. (2026). Another piece of the evidence puzzle: is prostate-specific membrane antigen PET–CT a valuable tool for risk stratification?. The Lancet Medical Imaging & Theranostics. https://doi.org/10.1016/j.lanmit.2026.100008

Vancouver

Atzinger A, Rosar F. Another piece of the evidence puzzle: is prostate-specific membrane antigen PET–CT a valuable tool for risk stratification?. The Lancet Medical Imaging & Theranostics. 2026. doi:10.1016/j.lanmit.2026.100008

BibTeX
@article{Atzinger2026,
  author = {Atzinger, Armin and Rosar, Florian},
  title = {Another piece of the evidence puzzle: is prostate-specific membrane antigen PET–CT a valuable tool for risk stratification?},
  journal = {The Lancet Medical Imaging & Theranostics},
  year = {2026},
  doi = {10.1016/j.lanmit.2026.100008}
}
Kostenlos starten →